Cellular Uptake and Efflux of Palbociclib In Vitro in Single Cell and Spheroid ModelsMaria Jové(St James's University Hospital), Chris Twelves(Beatson West of Scotland Cancer Centre)Journal of Pharmacology and Experimental TherapeuticsJune 13, 201910.1124/jpet.119.256693Cited by 11SaveCiteExport RISWatch citationsRelated PapersA phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days|British Journal of Cancer|2006|257